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Abstract
Background: In 2010, the diagnosis and treatment of IgE-mediated CMA were systematized in a GRADE guideline.
Objectives & methods: After 6 years, the state of the knowledge in diagnosis and treatment of CMA has largely
evolved. We summarize here the main advances, and exemplify indicating some specific points: studies aimed at
better knowledge of the effects of breastfeeding and the production of new special formulae intended for the
treatment of CMA. The literature (PubMed/MEDLINE) was searched using the following algorithms: (1) [milk allergy]
AND diagnosis; (2) [milk allergy] AND [formul*] OR [breast*], setting the search engine [6-years] time and [human]
limits. The authors drew on their collective clinical experience to restrict retrieved studies to those of relevance to a
pediatric allergy practice.
Results: Several clinical studies did address the possibility to diagnose CMA using new tools in vitro and in vivo,
or to diagnose it without any evaluation of sensitization. Some studies also addressed the clinical role of formulae
based on milk hydrolysates, soy, or rice hydrolysates in the treatment of CMA. Many studies have elucidated the
effects of selective nutrients in breastfed infants on their immunologic and neurologic characteristics.
Conclusions: Evidence-based diagnostic criteria should be identified for non-IgE-mediated CMA. Debate is ongoing
about the best substitute for infants with CMA. In particular, Hydrolyzed Rice Formulae have been widely assessed
in the last six years. In the substitute choice, clinicians should be aware of recent studies that can modify the
interpretation of the current recommendations. New systematic reviews and metanalyses are needed to confirm
or modify the current DRACMA recommendations.
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Background
Six years have passed since the World Allergy
Organization (WAO) Diagnosis and Rationale for Action
against Cow’s Milk Allergy (DRACMA) guidelines sys-
tematized the diagnosis, prognosis, and treatment of al-
lergy to cow's milk proteins (CMA) [1]. Since then,
advances have been made in all the fields covered by the
guidelines. In diagnosis, the possibility of interpreting
the pathology by molecular test has improved [2, 3].
Studies have been made on the use of patch tests [4]
and of new tests, such as the Basophil Activation Test,
in some clinical situations [5]. The possibility to use
clinical scores to diagnose non IgE-mediated CMA has
been proposed [6], and is now the subject of intense de-
bate [7, 8]. New studies have clarified the natural history
of the disease [9, 10] and the possible role of micro-
biome in shaping it [11]. The successful introduction of
baked products into the diet before tolerance develop-
ment to unprocessed milk changed our daily practice,
and it is now debated if this offers a new possibility to
modify it [12, 13]. However, the field where we made
the greatest strides is the replacement therapy. Many
new formulas have been developed, entering the every-
day use. These formulas are aimed to not only improve
their nutritional value, nutrient balance, and allergolo-
gic safety, but also include functional components,
some also found in formulas for normal children, some
specific for infants with CMA.
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In this article, we will offer an overview of CMA in its
development over the last six years. We will pay particu-
lar attention to the advances in the field of therapy, look-
ing at the unmet needs indicated in the DRACMA
guidelines, and to the way they have been dealt with (if
not met) by the scientific community. To this end, we
cite as an example some of the topics that may become
the subject of revision in the new guidelines.
2010–16: many more reasons for considering
breastfeeding as the first substitute in CMA
Faced with an infant with CMA, the pediatrician must
dictate an avoidance regimen. This will include a sub-
stitute; the best is – of course – breastfeeding with a
mother’s diet free of milk products [1]. Breastfeeding is
strongly recommended as the preferred way of infant
feeding [14]. Compared to formula-fed infants, the
breastfed show:
– Better brain development
– Different growth patterns
– Different nutritional status
– Better immunologic system development &
immune responses
– Different gut microflora
– Fewer infections, of shorter duration.
Despite the fact that formulae are modeled after
breastmilk, the human milk composition maintains its
unique characteristics. It contains a series of inimitable
molecules with potential immune modulating activities.
Examples comprise:
– maternal antibodies, including anti-idiotypic
antibodies, able to sustain and regulate immune
cell populations through a priming of fetal and
neonatal cells;
– cytokines (TGF-β2, IL-10, thymic stromal
lymphopoietin) and chemokines, influencing
the development of allergy and atopic diseases;
– hormones and growth factors, influencing the
maturation of the infant gut and of the associated
lymphoid tissues;
– PUFAs, nucleotides, glycoproteins, oligosaccharides
and microRNA, able in turn to exert immune
functions.
Probably also for these reasons breastfeeding has been
shown to influence a series of outcomes, including the
establishment of gut microbiota, the prevention of over-
weight and obesity, the development of immunoallergic
parameters and the neural development.
This last aspect is being actively investigated, and in
the last few years offers us some new acquisitions that
can be of interest in the general management of CMA.
Breastfed babies display important structural differences
in the brain anatomy compared with those that received
infant formula: for instance, they present a longer corpus
callosum, a higher ganglyothalamic ovoid diameter [15],
a higher cortical thickness in parietal lobules [16].
Probably related to these effects, breastfeeding posi-
tively influences cognitive development and general
intelligence [14].
From studies in cohorts of non-allergic infants it is
known that the neural programming displays some ‘win-
dows of plasticity’, during which environmental, nutri-
tional, and microbiological factors may influence the
brain function, generating different behavioral compe-
tence trajectories [17]. Many animal studies have fo-
cused on the effects of nutrition on brain development
demonstrating that changes in dietary nutrients can alter
brain morphology as well as its biochemical functions.
Before the year 2010, however, much of the evidence
from human studies was retrospective. Then epidemio-
logical birth cohort studies indicated that folate, n-3
fatty acids, iodine and iron administered in pregnancy
may influence the brain development in healthy chil-
dren [18]. In particular, from the ALSPAC cohort we
know that:
– Maternal seafood intake during pregnancy of less than
340 g per week is associated with increased risk of
their children being in the lowest quartile for verbal
intelligence quotient (IQ), compared with mothers
who consumed more than 340 g per week [19]
– Low maternal seafood intake was also associated with
increased risk of suboptimum outcomes for prosocial
behaviour, fine motor skills, communication, and
social development scores. For each outcome
measured, the lower the intake of seafood during
pregnancy, the higher the risk of suboptimum
developmental outcome [19]
– Iodine deficiency during pregnancy is associated
with negative cognitive outcomes [19, 20].
After birth, the more implicated nutrients in the global
development of infants are protein supply, PUFAs,
Vitamins B12, C, A and D, iron, iodine, choline, zinc,
selenium, and copper. Independently or in combination,
their nutritional availability may influence cognitive per-
formance behavior [21]. Other studies failed to identify
positive effects of breastfeeding on early life intelligence
and cognitive growth from toddlerhood through adoles-
cence [22], while an improved performance in intelligence
of breastfed children was found at age 30 [23]. Taken
together, the recent human studies indicate that the
association among breastfeeding and improved per-
formance in intelligence tests is not casual [24].
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As a case in point, essential fatty acids play a central
role in brain development of infants: humans can
synthesize saturated and monounsaturated fatty acids
but cannot synthesize the n-3 and the n-6 families of
PUFA. The parent fatty acids of these families, alpha
linolenic acid (18 carbons, three double bonds with the
first double bond in the n-3 position, C18:3n-3, ALA)
and linoleic acid (C18:2n-6, LA) are essential fatty acids
and must be present in the diet. ALA is converted to
eicosapentaenoic acid (C20:5 n-3, EPA) then to docosa-
hexaenoic acid (C22:6n-3, DHA), while LA is converted
to arachidonic acid (C20:4n-6, AA). DHA is a critical
component of cell membranes, especially in the brain
and retina. AA is both a membrane component and a
precursor to potent signaling molecules, the prosta-
glandins and leukotrienes. The human milk always
contains both AA and DHA, while in the past infant
formulae had neither. Interventional studies failed to
find evidence that prenatal fish-oil (and folic acid) sup-
plementation may influence the cognitive development
of children at 6.5 y of age, but a high DHA in maternal
erythrocytes at delivery was associated with a Mental
Processing Composite Score higher than the 50th
percentile in the offspring [25]. Also, associations of
maternal LC-PUFA status with child emotional and
behavioral problems were found in an epidemiologic
study [26]. Nowadays, special formulae for the treat-
ment of CMA are not in line with these characteristics
of HM (Table 1).
Another important component of breast milk is folic
acid; its appropriate availability at the onset of
pregnancy is associated with brain volume (Fig. 1). In
children with low maternal folate levels, the head grows
0.1 mm per week less than in the controls [27]. This
may translate in 1.9 million neurons and 1.9 billion
synapses less per week. Low maternal folate status during
early pregnancy was also found associated with a higher
risk of emotional and behavioral problems in the offspring
[28]. The use of prenatal folic acid supplements around
the time of conception has been associated with a lower
risk of autistic disorder [29]. Human milk provides
sufficient folate intake, essential for normal growth and
brain development; heat treatment in the breastmilk
banks may critically reduce its amount [30].
Breastfeeding also influences the gut microbiota. Its
establishment soon after birth is conditioned by factors
as the type of delivery (passage through the birth canal
vs. caesarean section), socioeconomic and climatic envir-
onment (born in developed vs. developing countries),
and immune system development during pregnancy,
antibiotic treatments, and contacts with parents, siblings
and hospital staff [31]. Dietary factors (breast vs. formula
feeding) are of prominent importance in this context.
The gut microbiota as a major topic of research inter-
est in biology has increased in recent years . Studies are
assessing the influence of variations in the composition
of the gut microbiota on diseases, ranging from inflam-
mation to obesity. Accumulating data now indicate that
the gut microbiota also communicates with the CNS —
possibly through neural, endocrine and immune path-
ways — and thereby influences brain function and be-
havior. Studies in germ-free animals and in animals
exposed to pathogenic bacterial infections, probiotic
bacteria or antibiotic drugs suggest a role for the gut
microbiota in the regulation of anxiety, mood, cognition
and pain [32]. It is now generally accepted that a stable
gut microbiota is essential for normal gut physiology
and contributes to appropriate signaling along the gut–
Table 1 General characteristics of infant formulas for CMA
CMA infant formula composition
Energy Similar to HM
Proteins Within normal recommended ranges, but CMP are hydrolysate, or whole proteins different
than human milk proteins; some supplemented with lysine, threonine or tryptophan
Fats Only 15 % have α-linolenic acid in similar amounts than HM; 31 % have more linoleic acid
than HM; 46 % do not include DHA; one includes 25 % palmitic acid in beta position.
Carbohydrates 70 % of special formulae are without lactose; all have a content of carbohydrates higher than HM
Micronutrients Fe≤ than in HM (risk of iron-deficiency). Content of other minerals should be reviewed considering other factors.
Vitamins A, E, D Need to be reviewed the doses depending on other factors (>25 % of children consumed <2/3 of the RDI of Ca,
Vitamins D and E).
Nucleotides 77 % have nucleotides
Choline Big variability in choline levels between different formulae.
Taurine 92 % have taurine
Carnitine 92 % have carnitine
Prebiotics 15 % include FOS/GOS
Probiotics 8 % include probiotics
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brain axis and, thereby, to the healthy status of the indi-
vidual, as shown on the left-hand side of Fig. 2. The
right-hand side of the figure indicates how intestinal
dysbiosis can adversely influence gut physiology, leading
to inappropriate gut–brain axis signaling and associated
consequences for CNS functions and resulting in disease
states. Conversely, stress at the level of the CNS can
affect gut function and lead to perturbations of the
microbiota [33]. Thus, the emerging concept of a micro-
biota–gut–brain axis suggests that modulation of the gut
microbiota may be a tractable strategy for developing
novel therapeutics for complex CNS disorders.
Of course, all these activities of breastfeeding are me-
diated through epigenetic activities of the diet, especially
during prenatal and early postnatal life. Diets high in
choline, methionine, folate, vitamin B6 and vitamin B12
increase DNA and histone methylation altering gene
expression and generating permanent changes in devel-
opment [34]. Early-life nutritional exposures, therefore,
can act on the development of asthma, allergy, and
obesity through epigenetic mechanisms [35].
From breastmilk to special formulae for children
with CMA
Patients with cow’s milk allergy and their breastfeeding
mothers must strictly avoid cow’s milk and cow’s milk
protein-based products. Particularly in young children, a
well-balanced diet with sufficient intake of calcium and
other essential nutrients must be warranted. When
non-breastfed, the staple food for infants with CMA are
special infant formulae. In an era when the benefits of
breastfeeding are better known, their use poses some
questions from a nutritional point of view:
– Are the apparently reassuring effects on growth
pattern of extensively hydrolyzed formulae (eHF),
rice hydrolyzed formulae (RHF), or amino acid
formulae (AAF) maintained over time?
– Have babies fed eHF, RHF, soy formulae (SF) or AAF
long-term effects on neurodevelopment similar to
those breastfed?
– If not, which are the effects associated to eHF,
RHF, SF or AAF feeding on neurodevelopment,
in relation to the different protein in the infant
formula composition respect to standard cow’s
milk infant formula?
– How does the use eHF, RHF, SF or AAF influence
the epigenetic process in the brain?
Fig. 1 Total brain volume of children born to mothers with
inappropriate and appropriate assumption of folic acid supplements
in the first trimester of pregnancy
Fig. 2 The gut-brain axis: interactions between microbiota and CNS functions
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– How does the “brain-body loop” work in children
fed with eHF, RHF, SF or AAF?
– Are eHF, RHF, SF or AAF modifying the development
of senses?
– Is the gut of the baby with CMA fed with eHF,
RHF, SF or AAF functioning the same? Which
will be the long-term consequences?
To assess these points, we must consider some differen-
tial characteristics of infant formulas for CMA vs human
milk and standard infant formulas for healthy babies
(Table 1). Taking into account these differences, most of
the studies have been focused on growth [36–38].
Safety has also been evaluated on clinical symptoms
(crying score, regurgitation score, stools, urticaria, eczema,
respiratory symptoms, [39]) and some biochemical
parameters as amino acid profile, plasma total protein,
albumin, prealbumin, calcium, magnesium, and alkaline
phosphatase [37]. All these studies have been reassuring
on the nutritional effects of special formulae. However,
we are far from understanding the role of all nutrients.
The data published so far report short-term assess-
ments; we need more data on the long-term follow-up
of infants who were fed the new infant formulas to fully
understand the role of these formulas and the func-
tional compounds which are being added to them on
these parameters [40].
Controversies on the dietary management of CMA
With all these limitations, when faced with a non-
breastfed infant with CMA the pediatrician must sug-
gest a substitution formula. The DRACMA guidelines
clearly suggest eHF as the first-line treatment for the
majority of situations (Table 2). RHF are considered
equivalent in the countries where they are available,
and AAF are suggested only in severe clinical situations
or in non-responder patients. In general, eHFs are nu-
tritionally adequate and well tolerated by children aller-
gic to cow’s milk and other foods, but their main
drawbacks are a bitter taste [41], cost (2–3 times vs.
standard formulae) and their potential to cause ana-
phylaxis. On the other hand, some specific sequences
of the peptides in eHF which could possess potential
immunomodulatory capacities, and, according to re-
cent suggestions, could lead to active tolerance induc-
tion [42]. RHF are considered a second-line resource
due to unavailability universally. Where available, RHF
can be considered instead of eHF. AAFs are safe but
are exorbitantly expensive (6–8 times the cost of eHFs)
and not widely available [43]. Thus, which factors
should the pediatrician take into account in choosing
the right substitute? We develop here some simple
considerations about the pros and cons of the different
types of formulae, starting with the definition of food
allergen.
Table 2 Choosing the appropriate substitute formula in different presentations (original source: DRACMA guidelines [1])
Clinical presentation 1st choice 2nd choice 3rd choice
Anaphylaxis AAFa eHFe, d SF
Immediate gastrointestinal allergy eHFd, b AAFf/SFg
Food protein-induced enterocolitis syndrome (CMAES) AAF eHFc
Asthma and rhinitis eHFd, b AAFf/SFg
Acute urticaria or angioedema eHFd, b AAFf/SFg
Atopic dermatitis eHFd, b AAFf/SFg
Gastroesophageal reflux disease (GERD) eHFb AAF
Allergic eosinophilic oesophagitis AAF
Cow’s milk protein-induced enteropathy eHFd, b AAF
Constipation eHFb AAF Donkey milki
Severe irritability (colic) eHFb AAF
CM protein-induced gastroenteritis and proctocolitis eHFb AAF




dSubject to local availability, RHF can be considered instead than eHF (7.4)
eSubject to a negative SPT with the specific formula (panel recommendation)
fAAF if a relatively high value on avoiding sensitization by SF and/or a low value on resource expenditure are placed
gSF if a relatively low value on avoiding sensitization by SF and/or a high value on resource expenditure are placed
hThis suggestion attributes a high value on avoiding exposure to even residual antigenic cow’s milk proteins
iBased on reports from one case series
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Milk allergens and eHF
Children allergic to cow’s milk are not allergic to the
milk as a whole, but to some of its proteins; and neither
to the protein itself, but to some specific parts able to
attach specific IgE, called epitopes. Thus, proteins are
composed of a more or less long chain of amino acids,
and only some parts of this chain are able to attach spe-
cific IgE [44]. Cow’s milk contains several proteins, some
of which are considered major allergens, some minor
ones, while others have been rarely associated with re-
ports of clinical reactions. Caseins and whey proteins of
cow’s milk are listed in Table 3. Their epitopes can be of
two types. When a longitudinal sequence of AAs placed
in a given order is able to attach IgE, this is called a ‘se-
quential epitope’. However, in other cases this particular
sequence is fictitious, because it is not in fact a lineal
sequence of AAs, but the result of the spatial folding of
the protein that actually configures a sequence similar to
that from the former sequential epitope. They are also
able to attach IgE, and are called ‘conformational epi-
topes’. This folding can be a consequence of different
physic-chemical mechanisms such as hydrophobic inter-
action, electric bridges or di-Sulphur bridges. These con-
formational epitopes are quite common in proteins from
whey milk, and they are very thermo-labile, which is
why manufacturers of infant formulas use heat to induce
thermal hydrolysis of proteins and avoid the attachment
of specific IgE [45].
In the case of casein, containing mainly thermostable se-
quential epitopes, thermal hydrolysis is not sufficient. In
this case, manufacturers use enzymatic hydrolysis, mainly
with pepsin and trypsin, by which the protein is reduced to
small fragments, with the aim of splitting the sequential
epitopes. However, this splitting is blind and not epitope-
selective so that it is possible that allergenic peptides
persist.
The final process for the production of a hydrolysate
is to ultra-filtrate the product in order to remove
native whole proteins remaining, and fragments with
high MW.
The results of these processes are the so-called eHFs.
In these formulae, depending on the manufacturer, the
size of the peptides varies. For example, in the case of
whey or casein and whey formulas, Nestle declares that
0.3 % of the peptides contained in Alfaré® are between
2400 and 4000 Da, Nutricia that 4 % of peptides con-
tained in Almiron® Pepti are greater than 3000 Da,
Laboratorios Ordesa that 5 % of peptides of Blemil® Plus
FH are between 1000 and 5000 Da, and so on. However,
according to ESPHGAN, to meet the definition of eHF a
product has not only to prove DBPCFC-negative in a
proportion of CMA children greater than 90 % [46], but
it is also required that:
– all Peptides have a MW lower than 5000 Da;
– a high proportion of them must have a MW even
lower;
– the formula is uncontaminated with native whole
proteins [47].
With such a definition, is complete avoidance (the
must of CMA treatment) possible? Is a MW <5000 Da a
sufficient warranty of non-exposure to cow’s milk pro-
teins? Effector cells, as basophils and mast cells, express
in their surface high-affinity receptors to which specific
IgE attaches. When the density of IgE molecules
Table 3 The proteins of cow’s milk (original source: DRACMA guidelines [1])
Fraction Protein Allergen g/L % total protein MW (kDa) # AA pIa
Caseins Bos d 8 ~30 80
Alphas1-casein 12–15 29 23.6 199 4.9–5.0
Alphas2-casein 3–4 8 25.2 207 5.2–5.4
Beta-casein 9–11 27 24.0 209 5.1–5.4
Gamma1-casein 1–2 6 20.6 180 5.5
Gamma2-casein 11.8 104 6.4
Gamma3-casein 11.6 102 5.8
Kappa-casein 3–4 10 19.0 169 5.4–5.6
Whey proteins ~5.0 20
Alpha-lactalbumin Bos d 4 1–1.5 5 14.2 123 4.8
Beta-lactoglobulin Bos d 5 3–4 10 18.3 162 5.3
Immunoglobulin Bos d 7 0.6–1.0 3 160.0 - -
BSAb Bos d 6 0.1–0.4 1 67.0 583 4.9–5.1
Lactoferrin - 0.09 traces 800.0 703 8.7
aIsoelectric point
bBovine serum albumin
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attached to the cell membrane allows that a protein frag-
ment containing two epitopes bypasses two of these IgE
molecules, a release of the mediators contained in the
cytoplasm occurs, and these are ultimately responsible
for the allergic symptoms. On the other hand, it is well
known that peptides formed by around 25 amino acids
can contain two sequential epitopes, and peptides with
only 10 AAs can include one sequential epitope [48]. A
1500 Da peptide may contain 11 amino acids, a 3000 Da
peptide 22 and a 5000 Da peptide may contain 36 amino
acids. Thus, peptides with a MW between 3000 and
5000 Da could possibly carry two sequential epitopes,
whereas peptides with a MW of 1500 Da could contain
one sequential epitope. A molecule carrying two epi-
topes could well determine an allergic reaction, while
smaller fragments, containing only one sequential epi-
tope, are not able to establish a bridge between two IgE
molecules, and consequently the allergic reaction would
not take place. However, are these fragments neutral,
without any immunological effect? This is theoretically
improbable, although there exists contradictory evidence
in this sense. For example, an open non-randomized
study suggests that peptides contained in eHF, even
when tolerated by CMA children, can exert an immuno-
modulatory effect able to shorten the time for the acqui-
sition of tolerance to CM [49], while a prospective
randomized study reported the opposite. In this model,
the median duration of CMA was 56 months when in-
fants were fed an eHF, 28 months if they were fed a soy
formula, and 20 months using a rice hydrolyzed formula
[50]. Thus, sensu stricto, the use of eHFs does not com-
pletely avoid the causative protein. It can induce undesir-
able, sometimes severe reactions, and it can hypothetically
contribute to the persistence of sensitization. There are no
safe CM hydrolysates [51].
Other problems with eHFs may include palatability,
cost, a higher solute renal load, and possible effects of a
predigested formula in inducing delay in the intestinal
enzymatic maturation. Similar problems may arise with
elemental, amino-acid based formulae. Having said that,
to avoid such problems, a completely different protein
source (soy or rice) could be used.
Soy formulae
Soy-based formulae are well tolerated in infants with
IgE-mediated CMA but to a less extent in those with
non-IgE mediated CMA. Many nutritional pitfalls with
these formulae have been indicated in the past, the ma-
jority of which have been corrected by manufacturers.
Current soy formulas are supplemented with appropri-
ate quantities of limiting amino acids such as Methio-
nine, Taurine, and Carnitine [52]. They are not
deficient in iron, zinc, calcium, phosphorus. The
content in aluminum is more than 50 times greater in
soy formulas than in breastmilk, but this is even truer
for hydrolyzed formulas (80 times greater). However,
95 % of the ingested Aluminum is not absorbed in the
gut and the kidney excretes the absorbed 5 %, so there
are no differences in plasma aluminum levels in children
fed with different formulas. Similar considerations are
valid for Manganese. These two elements have been
blamed for possible neurological damages, but no men-
tal or developmental disorders have been detected
among children fed with soy formulas as compared to
cow’s milk formulas [53]. Soy formulae used to contain
phytates which were blamed for their chelating capacity,
preventing the appropriate absorption of several min-
erals and oligoelements. However, since the late eighties,
phytates are almost totally removed from the soy formu-
lae, resulting in substantially enhanced absorption of im-
portant micronutrients. Thus, a systematic review
proved no significant differences in several biochemical
parameters [54]. Raffinose and stachyose, responsible for
bacterial fermentation and secondary flatulence, are
nowadays removed from soybean products.
Two potential drawbacks remain for the use of soy
formulas. One is the concern about possible hormonal
effects on the reproductive system presumed due to phy-
toestrogens in the form of isoflavones (genistein, daidzen
and their glycosides) present in soy protein. To date, the
data do not support those concerns. The fertility and the
general health of young adults has not been found to be
affected by their exposure to soy formula as infants [55],
and isoflavones have also been associated with a
suppression of immune sensitization by suppressing
Dendritic Cell (DC) maturation and its subsequent DC-
mediated effector cell functions [56]. Masilamani et al.
reported that dietary isoflavones significantly reduced
the anaphylactic symptoms and mast cell degranulation
in vivo after peanut challenge in a murine model of pea-
nut allergy. Thus, they suggested dietary supplementa-
tion of soybean isoflavones as a possible novel strategy
to prevent the development of allergic reactions to food
[57]. The other problem to take into consideration is the
use of transgenic soy in formulae. According to data
from the US Department of Agriculture, up to 93 % of
soybean crops are transgenic [58]. Although the available
evidence suggests no deleterious effects on the human
genome, reluctance to use transgenic food persists [59].
Due to these nutritional issues, ESPGHAN recommends
not to use soy in infants with food allergy during the
first 6 months of life [60].
Rice hydrolised formulae
For all these reasons, a plausible alternative would be to
use rice-based formulas. Rice is one of the less allergenic
staple foods, reacting in <1 % of allergic children. It has
no lactose and no phytoestrogens. For this reason, it has
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been developed as non-allergenic product in rice protein
hydrolysates. These formulae are now in use for more
than 10 years in Italy (Plasmon Risolac®, Heinz - Milan),
in Spain (Blemil Plus Arroz Hidrolizado®, Laboratorios
Ordesa - Barcelona), and in France (Modilac Expert Riz®,
Sodilac – Paris; Novalac Riz®, Novalac - Paris). By en-
zymatic proteolysis, rice proteins have been hydrolyzed
in the following ways:
– In Risolac®, 44 % of peptides have MW< 1000 Da,
43 % 1000–2000 Da, 13 % 2000–4000 Da;
– In Blemil Plus Arroz Hidrolizado® & Modilac Riz®,
96,6 % of peptides have MW< 5000 Da (26,8 % <
300 Da, 29,9 % with 300–1000 Da, 35,2 % 1000–
5000 Da), and up to 10 % are free amino –acids [52]
– In Novalac Rice®, 95 % of peptides have MW<
1000 Da, and 99,4 % have MW ≤ 5000 Da [52].
The biological value of rice proteins is naturally different
from bovine proteins: although they are rich in essential
amino acids, three limiting essential amino-acids do not
reach the respective value contained in breastmilk
(Table 4). Based on partially hydrolyzed rice proteins sup-
plemented with Lysine, Threonine, Tryptophan, Carnitine
and Taurine, Iron and Zinc, RHFs are safe to children
allergic to milk and soy [61] and to poliallergic infants
[62]. A Spanish open, randomized clinical trial compared
rice protein hydrolysate formula (Blemil Plus Arroz Hidro-
lizado® 1 & 2) versus casein hydrolysate (Blemil Plus FH®).
The 81 infants with CMA, median age 4.3 months, tol-
erated the formula in 100 % of cases [63]. To date, not
a single case of reaction to an RHF is reported among
children suffering from CMA.*Essential amino-acids
not reaching the respective value contained in
breastmilk
Their nutritional properties have been proved in
several studies [54, 64] judged sufficient to warrant their
safety by the metanalysis underlying the DRACMA
guidelines [1]. Hydrolysate rice protein formulae supply
68–71 kcal/100 mL. Some alarming data on the nutri-
tional effects of RHF were published 10 years ago.
Eighty-eight infants with atopic dermatitis, 58 of whom
with CMA confirmed at open challenge, were retro-
spectively evaluated. Fifteen were fed a rice-based hy-
drolysate formula (RHF), 17 a soy-based formula (SF),
26 an extensively hydrolysed casein formula (eHCF),
and 30 infants with AD without cow’s milk allergy
served as a control group (CG) [27]. No differences
were recorded in weight for age during first 2 years of
life between RHF, SF and eHCF group’s z-score. The
group fed RHF showed a reduction in weight vs control
group in the age intervals 9–12 months (p = 0.025) and
12–18 months (p = 0.020). By contrast, SF and eHCF
groups were comparable to the control group, except
for the 1st trimester of life (eHCF group significantly
lower). The authors concluded that these retrospective
data pose some questions on the nutritional adequacy
of rice-hydrolysate formulas.
More reassuring information came from later pro-
spective studies. A prospective clinical assessment of
tolerance to a rice-based hydrolysed formula was car-
ried out in 100 children allergic to cow’s milk [54]. All
patients were sensitized to cow’s milk and/or at least
one cow’s milk protein fraction and CMA was confirmed
at double blind, placebo-controlled food challenge
(DBPCFC) when not contraindicated. DBPCFC was car-
ried out with increasing doses of a rice-based hydrolysed
formula and all children tolerated it. Another pro-
spective study assessed growth adequacy between 6
and 12 months in 93 children with IgE-mediated
CMA, breastfed at least 4 months and weaned at 5–6
months. Infants were randomized to three types of
feeding formula:
– Soy (32 infants; Isomil 2®)
– Casein hydrolysate (31; Nutramigen®)
– Rice protein hydrolysate enriched in lysine and
threonine (30; Risolac 2®).
A reference group, non-randomized, was made of in-
fants with CMA breastfed until 12 months (n = 32). All
groups displayed low weight/age z-score at enrolment
(6 month); this was interpreted as an effect of CMA.
Infants fed casein or rice protein hydrolysates had
higher z-score weight/age than infants fed soy at 9 and
12 months. A quicker weight catch-up was found with
RHF than with eHF at 9 and 12 months. Infants fed rice
hydrolysate showed height/age z-score identical to
those fed soy and those breastfed at 9 and 12 months.
Table 4 Essential or semi-essential amino-acids in rice vs.
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Infants fed casein hydrolysate had a higher height/age
z-score at 9 and 12 months. These data showed that
rice hydrolysate ensured an appropriate growth [28].
More data on this aspect came from the Spanish study
mentioned above [55]. At enrolment, all infants had a
weight below the mean to Spanish reference, probably
due to CMA (as already seen in [28]). Weight for age,
height for age, and weight for height did not differ
among RHF- and eHF-fed children.
In a French study, 78 healthy term infants, <1 month
old, were exclusively fed hydrolyzed rice protein formula
(Modilac Riz®) until the introduction of solid foods in an
open-label, multicenter study. The change in the for-
mula was done because of digestive troubles (colics, gas,
and regurgitation) or risk of allergy. Infants presenting a
cow’s milk protein allergy were excluded. Their daily
weight gain over 5 months was 23.2 ± 4.3 g/day, identical
to WHO standards (22.2 ± 1.8 g/day, P = 0.09). The Z-
scores for weight, height, and BMI varied between +1.1
and −0.5 SD according to the WHO standards. Formula
acceptance and tolerance were both good [65]. Last, a
prospective trial assessed clinical tolerance of eRHF [30].
Forty infants (mean age, 3.4 months; range, 1–6 months)
with CMA confirmed by a food challenge tolerated the
eRHF with a symptom score significantly decreased from
the first month of intervention on. Those fed eRHF
showed a catch-up to normal weight gain from the first
month, and a normalization of the weight-for-age,
weight-for length, and BMI z-scores within the 6-month
study period. This study concluded that eRHF was toler-
ated by more than 90 % of children with proven CMA
with a 95 % confidence interval, indicating it as an
adequate and safe alternative to cow milk-based eHF.
From these studies, the allergologic and nutritional
safety of the RHFs is clear. Where available, these
products could become the first line treatment of
CMA even in severe forms.
Conclusions
Six years after the publication of DRACMA guide-
lines, new science in breastfeeding makes even clearer
that its benefits are inimitable. In the case of CMA,
every effort should be done to preserve the breast-
feeding. When this is not possible, many options are
available. Although we provided a review of some
points of interest, our indications will not necessarily
translate in to different recommendations after a re-
view of the DRACMA metanalyses. To our under-
standing, however, some points have to be taken into
account:
– non IgE-mediated CMA should be better defined;
– First diagnosis and management should fall under
the DRACMA recommendations;
– The dietetic management of CMA depends on the
type of allergic reaction;
– CMP-based eHF may not guarantee a complete
avoidance;
– The possible tolerogenic role of exposure to milk
protein residues in eHF must be taken in account;
– Nutritional, economic, and allergologic aspects
should be appropriately balanced.
The accruing evidences on diagnosis and treatment
now make an update of the guidelines advisable. Be-
tween 2010 and 2016, DRACMA modified the diag-
nostic and prescriptive attitudes of pediatricians [66],
and the guidelines may be modified by the new evi-
dences. Following the strictest criteria for EBM, and
using the Grading of Recommendations Assessment,
Development and Evaluation (GRADE) approach, the up-
dated DRACMA aims to answer more clinical questions,
adhering to the needs of pediatricians worldwide.
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